--- title: "Neoadjuvant Gastroesophageal Adenocarcinoma Alliance A022102 | Sutter Health" description: "Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma" url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Gastroesophageal Adenocarcinoma Alliance A022102 # Neoadjuvant Gastroesophageal Adenocarcinoma Alliance A022102 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05677490). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. ![Uma Suryadevara, M.D.](https://dyn.mktgcdn.com/p/uTm9De_Et4uRHg7A6rYTiaGafphjbp8QnGTH11anoUI/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Uma Suryadevara, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/uma-suryadevara-md-1049681015) ## Sub-Investigator [Kim-Son Nguyen, M.D., MPA](https://www.sutterhealth.org/research/investigators/kim-son-nguyen-md-mpa-1049681024) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Gastroesophageal%20Adenocarcinoma%20Alliance%20A022102%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment - Clinical trial ### [Acute Myeloid Leukemia Dental Wipes COG ACCL2531](https://www.sutterhealth.org/research/clinical-trials/acute-myeloid-leukemia-dental-wipes-cog-accl2531-2099128841) A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB](https://www.sutterhealth.org/research/clinical-trials/adjuvant-advance-ovarian-cancer-framework-01-j5e-mc-jzxb-2066913418) FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Gastroesophageal Adenocarcinoma Alliance A022102"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232#medicalwebpage","name":"Neoadjuvant Gastroesophageal Adenocarcinoma Alliance A022102","description":"Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232#breadcrumblist"},"mentions":[{"@type":"Person","name":"Uma Suryadevara, M.D.","url":"https://www.sutterhealth.org/research/investigators/uma-suryadevara-md-1049681015","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232#medicaltrial","name":"Neoadjuvant Gastroesophageal Adenocarcinoma Alliance A022102","alternateName":"Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gastroesophageal-adenocarcinoma-alliance-a022102-1094798232","description":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy.","identifier":"NCT05677490","code":{"@type":"MedicalCode","codeValue":"NCT05677490","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT05677490","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Gastrointestinal Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```